The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Bekolo, Cavin Epie ^a   Nguena, Modestine Becker ^b   Ewane, Leonard ^c   Bekoule, Patrick Sylvestre ^d   Kollo, Basile ^e  

^a Centre Médical d'Arrondissement de Baré   (Cameroon)

^b Centre d'Enseignement Spécialisé des Techniques d'Analyses Médicales de Yaounde   (Cameroon)

^c UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^d Regional Hospital of Nkongsamba   (Cameroon)

^e UNIVERSITY OF DOUALA   (Cameroon)

Author keywords

Antiretroviral therapy; Blood lipids; Cameroon; HIV

Indexed keywords

CHOLESTEROL, HDL; CHOLESTEROL, LDL; TRIGLYCERIDES;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD; CAMEROON; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; EPIDEMIOLOGY; FEMALE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SMOKING; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMEROON; CD4 LYMPHOCYTE COUNT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SMOKING; TRIGLYCERIDES; YOUNG ADULT;

EID: 84898034615     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-236     Document Type: Article

References (34)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS), Global Report: UNAIDS Report on the Global AIDS Epidemic 2013 Geneva: UNAIDS 2013
2. HIV-associated metabolic and morphologic abnormality syndrome:Welcome therapy may have unwelcome effects. Cohan GR, Postgrad Med 2000 107 141 146 10778417 (Pubitemid 30212181)
3. HIV and HAART-Associated Dyslipidemia. Feeney ER, Mallon PW, Open Cardiovasc Med J 2011 5 49 63 10.2174/1874192401105010049 21643501
4. Dyslipidemia and its Treatment in HIV Infection. Grunfeld C, Top HIV Med 2010 18 3 112 118 20921577
5. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy, Results from the DAD study. Friis-Moller N, Weber R, Reiss P, AIDS 2003 17 8 1179 1193 10.1097/00002030-200305230-00010 12819520 (Pubitemid 36667761)
6. Central Bureau of the Census and Population Studies, La population du Cameroun en 2010 Yaounde: Central Bureau of the Census and Population Studies 2010
7. National Institute of Statistics, Enquête Démographique et de Santé et à Indicateurs Multiples EDS-MICS 2011 Yaounde: National Institute of Statistics 2011
8. Ministere de la Sante Publique du Cameroun, Rapport annuel des activités de lutte contre le VIH et les IST au Cameroun Yaounde: Ministere de la Sante Publique du Cameroun 2011
9. The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon. Ngondi JL, Oben J, Forkah DM, Etame LH, Mbanya D, AIDS Res Ther 2006 3 19 10.1186/1742-6405-3-19 16859567 (Pubitemid 44400332)
10. Lipid peroxidation and total cholesterol in HAART-naïve patients infected with circulating recombinant forms of human immunodeficiency virus type-1 in Cameroon. Teto G, Kanmogne GD, Torimiro JN, Alemnji G, Nguemaim FN, Takou D, Nanfack A, Asonganyi T, PLoS ONE 2013 8 6 65126 10.1371/journal.pone. 0065126 23762297
11. Ngogang J, Oumarou A, Mbuagbaw J, Mbanya D, Lipides et lipoprotéines des sujets camerounais VIH positifs naifs aux antirétroviraux PAMJ Proceedings of the 6th Congress of Cameroon Cardiac Society. 2008 10
12. Serum lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: a case-control study. Nguemaim NF, Mbuagbaw J, Nkoa T, Alemnji G, Teto G, Fanhi TC, Asonganyi T, Same-Ekobo A, HIV Med 2010 11 6 353 359 20345886
13. World Health Organisation, Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach 2010 revision. http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf
14. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. Pefura Yone EW, Betyoumin AF, Kengne AP, Folefack FJK, Ngogang J, AIDS Res Ther 2011 8 33 10.1186/1742-6405-8-33 21943115
15. Rural and urban differences in metabolic profiles in a Cameroonian population. Lissock CNAA, Sobngwi E, Ngassam E, Ngoa LSE, PAMJ 2011 10 1
16. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 6 499 502 4337382
17. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001 285 19 2486 2497 10.1001/jama.285.19.2486 11368702
18. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. Tadewos A, Addis Z, Ambachew H, Banerjee S, AIDS Res Ther 2012 9 1 31 10.1186/1742-6405-9-31 23095661
19. Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam Tanzania. Armstrong C, Liu E, Grinspoon S, Okuma J, Spiegelman D, Guerino C, Njelekela M, Fawzi W, Hawkins C, J Acquir Immune Defic Syndr 2011 57 2 141 145 10.1097/QAI.0b013e318219a3d1 21436713
20. Management of dyslipidemia in HIV-infected patients. Malvestutto CD, Aberg JA, Clin Lipidol 2011 6 4 447 462 10.2217/clp.11.25 22216062
21. Sex differences in HAART-associated dyslipidaemia. Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, Rieger A, Wagner OF, Quehenberger P, AID 2001 15 6 725 734 10.1097/00002030-200104130-00008 (Pubitemid 32423220)
22. Lipid profile of anti-retroviral treatment-naive HIV-infected patients in Jos Nigeria. Daniyam C, Iroezindu M, Ann Med Health Sci Res 2013 3 1 26 30 10.4103/2141-9248.109468 23634325
23. Correlation between HIV disease and lipid metabolism in antiretroviral-naive HIV-infected patients in Japan. Oka F, Naito T, Oike M, Imai R, Saita M, Inui A, Mitsuhashi K, Isonuma H, Shimbo T, J Infect Chemother 2012 18 1 17 21 10.1007/s10156-011-0275-5 21735099
24. Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Kiage JN, Heimburger DC, Nyirenda CK, Wellons MF, Bagchi S, Chi BH, Koethe JR, Arnett DK, Kabagambe EK, Lipids Health Dis 2013 12 50 10.1186/1476-511X-12-50 23575345
25. Impact of HIV infection and HAART on serum lipids in men. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsle LA, JAMA 2003 289 22 2978 2982 10.1001/jama.289.22.2978 12799406 (Pubitemid 37430100)
26. Ministere de la Sante Publique du Cameroun, Directives nationales de prise en charge par les antirétroviraux des personnes (Adultes et Adolescents) infectées par le VIH Yaounde: Ministere de la Sante Publique du Cameroun 2010
27. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA, HIV Med 2006 7 2 85 98 10.1111/j.1468-1293.2006.00346.x 16420253
28. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). Eron JJ Jr, Murphy RL, Peterson D, AIDS 2000 14 1601 1610 10.1097/00002030-200007280- 00016 10983647
29. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Gallant JE, Staszewski S, Pozniak AL, De Jesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, JAMA 2004 292 2 191 201 10.1001/jama.292.2.191 15249568 (Pubitemid 38917996)
30. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P, PLoS Med 2004 1 1 19 10.1371/journal.pmed.0010019 15526045
31. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. Craig WY, Palomaki GE, Haddow JE, BMJ 1989 298 6676 784 788 10.1136/bmj.298.6676.784 2496857 (Pubitemid 19084522)
32. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. Triant VA, Lee H, Hadigan C, Grinspoon SK, J Clin Endocrinol Metab 2007 92 7 2506 2512 10.1210/jc.2006-2190 17456578 (Pubitemid 47037350)
33. Alcohol consumption, progression of disease and other comorbidities, and responses to antiretroviral medication in people living with HIV. Neuman MG, Schneider M, Nanau RM, Parry C, AIDS Res Treat 2012 2012 751827 22496971
34. Alcohol intake and cardiovascular risk factor profile in men participating in the WOBASZ study. Waskiewicz A, Sygnowska E, Kardiol Pol 2013 71 4 359 365 10.5603/KP.2013.0063 23788341